R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.
Donna Przepiorka,Donna Przepiorka,Cindy Ippoliti,Issa F. Khouri,Paolo Anderlini,Rakesh Mehra,Sergio Giralt,James Gajewski,Herbert A. Fritsche,Albert B. Deisseroth,Karen R. Cleary,Richard E. Champlin,Koen van Besien,Borje S. Andersson,Martin Korbling +14 more
TL;DR: The use of blood stem cell grafts and FK506 can reduce the early mortality after allogeneic transplantation for advanced leukemia and the diagnosis of acute lymphoblastic leukemia was associated with a higher risk of treatment-related mortality.
Journal ArticleDOI
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Muzaffar H. Qazilbash,Rima M. Saliba,Yago Nieto,Gaurav Parikh,Matteo Pelosini,Fatima B. Khan,Roy B. Jones,Chitra Hosing,Floralyn Mendoza,Donna M. Weber,Michael Wang,Uday R. Popat,Amin M. Alousi,Paolo Anderlini,Richard E. Champlin,Sergio Giralt +15 more
TL;DR: Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM.
Journal Article
Blood stem cell procurement: Donor safety issues
TL;DR: Allogeneic transplantation of rhG-CSF-mobilized peripheral blood stem cells (PBSCs) is now being increasingly performed, but safety considerations for hematologically normal PBSC donors have not been fully addressed, and a consensus is gradually emerging on several issues.
Journal ArticleDOI
Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Maro Ohanian,Hagop M. Kantarjian,Alfonso Quintás-Cardama,Elias Jabbour,Lynne V. Abruzzo,Srdan Verstovsek,Gautam Borthakur,Farhad Ravandi,Guillermo Garcia-Manero,Richard E. Champlin,Sherry Pierce,Mona Lisa Alattar,Long Xuan Trinh,Raja Luthra,Alessandra Ferrajoli,Tapan M. Kadia,Susan O'Brien,Jorge E. Cortes +17 more
TL;DR: TKIs should be considered standard initial therapy for patients with AP at the time of diagnosis and overall survival at 36 months was 87% with imatinib and 95% with 2GTKIs.
Journal ArticleDOI
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
Gary J. Schiller,James Gajewski,Stephen D. Nimer,Mary C. Territo,Winston G. Ho,Myung Lee,Richard E. Champlin +6 more
TL;DR: It is concluded that intermediate dose cytarabine did not substantially improve results of induction chemotherapy for acute myeloid leukaemia.